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Short-chain enoyl-CoA hydratase (SCEH or ECHS1) deficiency is a rare inborn error of metabolism
caused by biallelic mutations in the gene ECHS1 (OMIM 602292). Clinical presentation includes
infantile-onset severe developmental delay, regression, seizures, elevated lactate, and brain MRI
abnormalities consistent with Leigh syndrome (LS). Characteristic abnormal biochemical findings are
secondary to dysfunction of valine metabolism. We describe four patients from two consanguine-
ous families (one Pakistani and one Irish Traveler), who presented in infancy with LS. Urine organic
acid analysis by GC/MS showed increased levels of erythro-2,3-dihydroxy-2-methylbutyrate and 3-
methylglutaconate (3-MGC). Increased urine excretion of methacrylyl-CoA and acryloyl-CoA related
metabolites analyzed by LC-MS/MS, were suggestive of SCEH deficiency; this was confirmed in
patient fibroblasts. Both families were shown to harbor homozygous pathogenic variants in the
ECHS1 gene; a c.476A>G (p.Gln159Arg) ECHS1variant in the Pakistani family and a c.538A>G,
p.(Thr180Ala) ECHS1 variant in the Irish Traveler family. The c.538A>G, p.(Thr180Ala) ECHS1 vari-
ant was postulated to represent a Canadian founder mutation, but we present SNP genotyping data
to support Irish ancestry of this variant with a haplotype common to the previously reported Cana-
dian patients and our Irish Traveler family. The presence of detectable erythro-2,3-dihydroxy-2-
methylbutyrate is a nonspecific marker on urine organic acid analysis but this finding, together with
increased excretion of 3-MGC, elevated plasma lactate, and normal acylcarnitine profile in patients
with a Leigh-like presentation should prompt consideration of a diagnosis of SCEH deficiency and
genetic analysis of ECHS1. ECHS1 deficiency can be added to the list of conditions with 3-MGA.
.......................................................................................................................................................................................
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1 | INTRODUCTION
Biallelic mutations in the ECHS1 gene (OMIM 602292) lead to a
deficiency of short-chain enoyl-CoA hydratase (SCEH/crotonase
EC4.2.1.17) resulting in a rare inborn error of valine metabolism (Haack
et al., 2015; Peters et al., 2014; Sakai et al., 2015; Tetreault et al.,
2015). Clinical presentation includes infantile-onset of severe develop-
mental delay and regression and seizures, with elevated plasma lactate
and brain MRI abnormalities consistent with Leigh syndrome (LS) as
described by Denis Leigh in 1951 (Leigh, 1951) and more recently by
Baertling et al. in 2014 (Baertling, 2014). Genetic diagnosis of SCEH
deficiency can be complicated by the clinical, radiological, and biochem-
ical overlap with mitochondrial encephalopathic disorders; often occur-
ring with respiratory chain complex deficiencies (Ferdinandusse et al.,
2015; Sakai et al., 2015) or pyruvate dehydrogenase (PDH) deficiency
(Bedoyan et al., 2017; Ferdinandusse et al., 2015; Peters et al., 2014).
Five enzymes are involved in the mitochondrial degradation of
valine to propionyl-CoA: isobutyryl-CoA dehydrogenase, short-chain
enoyl-CoA hydratase (SCEH), 3-OH-isobutyryl-CoA hydrolase (HIBCH),
3-hydroxyisobutyric acid dehydrogenase (HIBADH), and methylmalo-
nate semialdehyde dehydrogenase (Figure 1); defects in these enzymes
cause inborn errors of valine degradation (Peters et al., 2014; Wanders,
Duran, & Loupatty, 2012).
Deficiency of SCEH which converts unsaturated trans-2-enoyl-
CoA species to the corresponding 3(S)-hydroxyacyl-CoA (Haack et al.,
2015; Peters et al., 2014; Sakai et al., 2015; Tetreault et al., 2015) and
deficiency of HIBCH (Brown et al., 1982; Ferdinandusse et al., 2013;
Loupatty et al., 2007; Soler-Alfonso et al., 2015; Stiles et al., 2015) that
catalyses the conversion of 3-OH-isobutyryl-CoA to 3-OH-isobutyrate,
the fourth and fifth steps of valine degradation, respectively, have been
associated with LS or Leigh-like syndrome and deficiencies of multiple
mitochondrial respiratory chain enzymes.
Accumulation of toxic methacrylyl-CoA and acryloyl-CoA, two
highly reactive intermediates that spontaneously react with sulfhydryl
groups of, for example, cysteine, and cysteamine, is suspected to cause
brain pathology and the biochemical pattern found in HIBCH and
SCEH deficiencies (Ferdinandusse et al., 2013; Loupatty et al., 2007;
Peters et al., 2014). SCEH also catalyzes the second step of the
b-oxidation of short-chain fatty acids, that is, the hydration of
a,b-unsaturated enoyl-CoAs to produce b-hydroxyacyl-CoAs
(Kanazawa et al., 1993). It has been speculated that it is both the
b-oxidation defect and the block in L-valine metabolism that contribute
to the pathology in SCEH deficiency (Haack et al., 2015). However,
Ferdinandusse et al. (2013) presented evidence that despite its broad
substrate specificity, SCEH appears to be crucial in valine catabolism,
but only of limited importance for mitochondrial fatty acid oxidation
and may not play a significant role in isoleucine metabolism.
Peters et al. (2014) described the metabolite erythro-2,3-dihydroxy-
2-methylbutyrate in urine of patients with SCEH deficiency. While the
exact origin of 2-methyl-2,3-dihydroxybutyrate is currently unknown,
we previously noted this metabolite in patients with lactic acidosis of
unknown etiology, and in patients with genetically proven metabolic
disorders including glycogen storage disease type 1a (OMIM 232200),
propionic acidemia (propionyl-CoA carboxylase deficiency, OMIM
232000), methylmalonic aciduria (methylmalonyl-CoA mutase defi-
ciency, OMIM 251000), PDH deficiency (OMIM 300502), and multiple
FIGURE 1 Valine catabolic pathway showing formation of metabolites listed in Table 4, which are abnormal in SCEH and HIBCH
deficiency. The metabolic origin of 2,3-dihydroxy-2-methylbutyrate is currently unclear. Enzymes are numbered: 25propionyl-CoA carbox-
ylase; 35 (R)-methylmalonyl-CoA mutase; 55 isobutyryl CoA dehydrogenase [Color figure can be viewed at wileyonlinelibrary.com]
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carboxylase deficiency due to biotinidase deficiency (OMIM 609019).
Despite complete deficiencies of the enzymatic activities in fibroblasts,
Ferdinandusse and co-workers could not detect 2,3-dihydroxy-2-meth-
ylbutyrate in the supernatant of patients’ cultured fibroblasts (Ferdinan-
dusse et al., 2015). 2,3-dihydroxy-2-methylbutyrate exists as two
isomers, erythro and threo. Erythro 2,3-dihydroxy-2-methylbutyrate is
elevated in urine of patients with pathogenic ECHS1 and HIBCH variants
and propionate defects and clearly segregates when plotted against the
threo isomer, while the threo isomer appears to be dietary related
(James Pitt, unpublished observation; Peters et al., 2015).
Given the segregation of erythro 2,3-dihydroxy-2-methylbutyrate
with metabolic dysfunction, we retrospectively reviewed urine organic
acid chromatograms analyzed in the Metabolic Laboratory, Department
of Paediatric Laboratory Medicine in Temple Street Children’s Univer-
sity Hospital from 2007 to 2010 and identified eight patients with
increased erythro-2,3-dihydroxy-2-methylbutyrate without a diagnosis;
of these, two were possible candidates for either SCEH or HIBCH defi-
ciencies (Patient 1 and Patient 2). Two siblings of Patient 2 born after
2010 were also included (Patients 3 and 4). We describe four patients
from two consanguineous families (Patient 1 from a Pakistani family
and Patients 2–4 from an Irish Traveler family) who presented in
infancy with LS. All had similar clinical features including developmental
delay/regression, faltering growth, hypotonia, seizures, and apneic epi-
sodes (Tables 1 and 2). All had previously undergone extensive investi-
gations without reaching a diagnosis.
2 | PATIENTS AND METHODS
2.1 | Patient reports
Patient 1 was the first child (male) born to consanguineous Pakistani
parents. He was born by emergency cesarean section at 37 weeks gesta-
tion because of intrauterine growth retardation. Birth weight was 2.6 kg
(5th percentile). Initially, he was slow to feed and his parents noted there
was excessive crying. Global developmental delay was apparent at 5
months of age with central hypotonia, peripheral hypertonia, nystagmus,
and failure to visually fix or follow. EEG was normal at 8 months; how-
ever, seizures commenced by 1 year of age and proved difficult to con-
trol. He was not dysmorphic but had hypertrichosis. Growth was
suboptimal with weight less than the 0.4th percentile for age and sex.
At 3 years, he had profound global developmental delay with
regression of feeding skills, poor swallow, and chronic vomiting. A per-
cutaneous endoscopic gastrostomy (PEG) tube was inserted to improve
feeding which led to some weight gain. Apneic episodes started and
became frequent. He had episodes of aspiration pneumonia and he
died just before his fourth birthday. His parents subsequently had two
further unaffected children (Tables 1 and 2).
Patient 2 was the eldest child (male) born to consanguineous Irish
Traveler parents by vaginal delivery at full term following an uneventful
pregnancy. Birth weight was 3.7 kg. From 3 months of age motor
developmental delay was noted. He had central hypotonia and
TABLE 1 Summary of clinical features of four patients with ECHS1 deficiency
Patient 1 Patient 2 Patient 3 Patient 4
Gender Male Male Female Male
Birth history ECS, 3714 IUGR First sibling
Term baby, SVD
SVD, 37 weeks (sibling RIP at
21 months)
Third affected sibling
SVD, 3415
Birth weight 2.6 kg 3.7 kg 3.26 kg 2.31 kg
Age at presentation 5 months 3 months 5 months 2 weeks
Age at death 4 years 21 months 28 months 13 months
Initial presentation Poor feeding, excessive
crying. Head lag, central
hypotonia, peripheral
hypertonia, Nystagmus
Global delay
No neonatal concerns
FTT, central hypotonia,
hepatosplenomegaly
No neonatal concerns
Significant faltering growth,
motor delay, central hypo-
tonia, hepatomegaly
Feeding problems, irritable,
hypotonic
Seizures From 11 months Ocular flutters from 9
months
From 5 months From 9 months
Faltering growth Weight 2nd percentile at
birth, <0.4th percentile at
1 year, improvement post
PEG insertion
At 19 months failure to gain
weight at 7.66 kg (<3rd
percentile) NG tube in-
serted at 19 months
5 months OFC at 0.4th
percentile; weight at 2nd
percentile. NG fed at 15
months, PEG inserted at
20 months
Weight 9th percentile at
birth, <0.4th percentile
at 12 weeks. NG fed
then PEG inserted at
10 months
Global developmental
delay and regression
Profound developmental
delay with loss of skills
Gross psychomotor delay
with loss of skills
Profound developmental
delay with loss of skills
Profound developmental
delay with loss of skills
Other clinical features Increased oral secretions,
chronic vomiting, apnea
Dyskinetic CP Dystonic posturing, apnea Profound irritability, apnea
CP5 cerebral palsy; ECS5 emergency cesarean section; IUGR5 intra uterine growth retardation; MRS5magnetic resonance spectrosopy;
OFC5occipital frontal circumference; PEG5 percutaneous endoscopic gastrostomy; SVD5 spontaneous vaginal delivery.
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hepatosplenomegaly. He was failing to thrive and feeding difficulties
were noted. At 9 months of age weight was below the 0.4th percentile,
head circumference was below the 2nd percentile; he was reviewed by
the neurology team for suspected dyskinetic cerebral palsy. He had no
dysmorphic features. Gross motor delay was noted while his develop-
ment was felt to be appropriate in other areas. On examination his
spleen tip was palpable and liver was 3 cm below the costal margin.
Ocular flutters were noted but no seizures.
His nutrition was supplemented with nasogastric feeds. By 12
months of age he was globally developmentally delayed with regression
of motor skills. On examination he showed variable peripheral tone
with abnormal mouthing and tongue movements. He continued to
have prominent feeding issues and developmental regression. He
passed away at 21 months of age. A post mortem was not consented.
Patient 3 was the second child (female) born to this family. Her elder
brother (Patient 2) passed away approximately 18 months earlier without
a diagnosis at the time of his death. She was born by spontaneous vaginal
delivery at 37 weeks gestation and there were no concerns during the
pregnancy. She had a good birth weight of 3.26 kg (50th percentile). There
were no neonatal concerns initially, but in light of the family history a met-
abolic screen was performedwhich showed elevated lactate and abnormal
urinary organic acids (Table 3). Her echocardiogram initially showed left
ventricular hypertrophy but follow-up echocardiogramswere normal.
At 5 months of age she showed significant faltering growth; her
weight had fallen to the 2nd percentile and her head circumference
had fallen from 25th to 0.4th percentile. She was showing signs of
motor delay and central hypotonia with moderate head lag. Hepatome-
galy was noted at this stage. Seizure activity was first noted at 7
months of age. She developed problems with feeding and was found to
be aspirating on thin fluids. By 9 months of age there was significant
global developmental delay. Her feeding difficulties prompted insertion
of a nasogastric tube. At 15 months her seizure activity had increased
consisting of prolonged tonic episodes with tongue protrusion and eye
deviation. She was demonstrating abnormal movements and dystonic
posturing which were non-epileptic in nature.
At 20 months of age a PEG feeding tube was inserted. She was
noted to be developing apneic episodes of increasing frequency and
duration. At 2 years and 3 months of age, she was intubated and venti-
lated following a respiratory arrest and passed away 11 days later.
Patient 4 was the third affected sibling (male) in this Irish Traveler
family. He was born at 34 weeks gestation by spontaneous vaginal
delivery. His birth weight was 2.31 kg (9th percentile corrected for ges-
tation). He was noted to have feeding problems with oxygen desatura-
tion and irritability from the outset.
Investigations at 5 weeks of age showed raised lactate and abnor-
mal urinary organic acids, with a similar profile to his sister (Table 3). On
review at 12 weeks of age he was found to be irritable, hypotonic and
globally developmental delayed. He was not fixing and following and
had poor head control. He had significant faltering growth with weight
less than 0.4th percentile. At 5 months of age a nasogastric tube was
inserted. At 7 months of age he was having increasing feeding difficul-
ties and loose stools. A PEG tube was inserted at 10 months of age.
From 9 months of age seizures were noted which became more
frequent and prolonged over the following months. He was admitted
to hospital for a “breath holding” episode at 11 months of age. Further
developmental regression was noted at this stage; he had become
increasingly hypotonic. At 12 months of age he had a significant apneic
episode and an upper gastrointestinal bleed. He was intubated and
ventilated and had a prolonged hospital stay. He passed away shortly
after extubation at 13 months of age.
TABLE 2 Summary of MRI findings
Patient 1 Patient 2 Patient 3 Patient 4
T2W hyperintense signal:
Globus pallidi 11 11 11 11
Putamina 1 1 1 1
Caudate heads 1 1 1 1
Thalami 2 2 2 1
Cerebral crura 11 11 11 11
Periaqueductal gray matter 2 1 1 1
Pons 1 2 2 1
Cerebellum 2 2 2 1
Restricted diffusion: 1 1 1 1
Brain volume loss:
Supratentoria 11 1 11 11
Infratentorial 11 2 1 1
MRS (Lactate peak): 1 1 2 1
Summary Abnormal bilateral signal
in the basal ganglia,
midbrain, and dendate.
Dilation of ventricles,
significant progression
in cerebral, and cere-
bellar atrophy. Thin-
ning of corpus
callosum.
Abnormal symmetrical
bilateral signal in glo-
bus pallidus, putamen,
head of caudate nuclei,
subthalamic nuclei, and
cerebral peduncles.
Thalamus spared. No
atrophy.
Symmetrical abnormal
signal in globus pallidi,
cerebral crura, caudate
nuclei, putamina, lenti-
form nuclei. Prominent
sulci and volume loss.
Focal bilateral symmetri-
cal lesions in thalami,
abnormal signal in len-
tiform nuclei, and cau-
date nuclei, dilation of
ventricles, prominent
sulci, and volume loss.
1 Positive, 11 Markedly Positive,2Negative; MRS5magnetic resonance spectroscopy.
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This patient series involves four patients from two different
families. All four patients had similar clinical features and progres-
sion. They all had significant developmental delay and central hypo-
tonia was a common early sign. Faltering growth and progressive
feeding problems were prominent in all patients. As the clinical syn-
drome progressed, seizures and apneic episodes became more fre-
quent and severe.
2.2 | Brain magnetic resonance imagining (MRI) and
spectroscopy (MRS)
Patient 1 had a total of three MRI Brain examinations. On the initial
imaging at 6 months of age, there was pronounced symmetrical T2W
prolongation of the globus pallidi and cerebral crura with corresponding
restricted diffusion on apparent diffusion coefficient (ADC). Less
marked hyperintensity was evident in the putamen and caudate nuclei.
There was a lactate peak on MRS. The thalami, pons, and cerebellum
were not involved.
Progressive volume loss was evident on subsequent imaging, most
pronounced in the cerebellum. The corpus callosum was markedly
thinned on the patient’s last imaging at 35 months. There was no
restricted diffusion on ADC or an abnormal lactate peak on MRS on
the subsequent imaging.
Patient 2 had one single MRI Brain examination at 9 months of age.
There was bilateral symmetrical T2W increased signal intensity involving
the corpus striatum, cerebral peduncles, and the periaqueductal gray
matter. The thalami were not involved. Diffusion weighted imaging was
not performed. A lactate peak was present on MRS (Figure 2a,b).
Patient 3 had a total of three MRI brain scans. Her initial MRI at 5
weeks was normal. A subsequent MRI performed at 10 months demon-
strated T2W prolongation of the caudate heads, lentiform nuclei, and cer-
ebral crura with corresponding restricted diffusion on ADC. No
abnormality was detected on MRS. Generalized brain volume loss was
also evident.
There was further progressive brain volume loss, quite marked in
the cerebellum on her last MR Imaging at 28 months. There was T2W
hyperintensity involving the corpus striatum, which demonstrated vol-
ume loss in the interval. There were new areas of restricted diffusion,
involving the hypothalamus (Figure 2c). MRS was normal.
Patient 4, the youngest of the three siblings had three MRI brain
examinations. The initial MRI at 6 weeks corrected gestational age,
showed mild delay of myelination. On subsequent MRI at 10 months
of age, there was extensive abnormal symmetrical hyperintensity in
caudate nuclei, lentiform nuclei, cerebral crura, periaqueductal gray
matter, and bilateral thalami. T2W prolongation was also noted in the
posterior tegmental tracts of the medulla.
On his last imaging at 12 months of age, there was marked brain
volume loss with prominent sulci and extra-axial spaces. There was also
abnormal T2W hyperintense signal involving the cerebellar gray matter,
posterior medulla, periaqueductal gray matter, cerebral crura, thalami,
and corpus striata. There were new areas of restricted diffusion seen in
the caudate heads. A lactate peak was evident on MRS.
TABLE 3 Biochemical results of extensive investigations of four patients with ECHS1 deficiency
Patient 1 Patient 2 Patient 3 Patient 4
Plasma lactate
(mmol/L)
1.47–>5.46
(0.6–2.4)
2.46
(0.6–2.4)
1.50–>5.68
(0.6–2.4)
1.92–>4.92
(0.6–2.4)
Plasma alanine
(mmol/L)
337–>764
(176–480)
599
(0–675)
423–>471
(0–675)
383–>559
(176–480)
Plasma proline
(mmol/L)
256–>717
(89–287)
468
(0–435)
211
(0–435)
277–>300
(89–287)
Acylcarnitine analysis
(DBS)
Normal profile
Slight increase in C4OH/
isoC4OH
Not performed Slightly decreased free
carnitine and long
chain AC. C4OH/iso-
C4OH not increased
Normal profile
C4OH/isoC4OH not
increased
Organic acid analysis Mild increases in
3-MGC
3-HIVA
2,3-dihydroxy-2-
methylbutyrate
Slight increases in
3-MGC
2,3-dihydroxy-2-
methylbutyrate
Marked lactate
Slight increase in MMA
Mild increase in
3-MGC
2,3-dihydroxy-2-
methylbutyrate
Mild dicarboxylic
aciduria
Slight increases in MMA
3-MGC
2,3-dihydroxy-2-
methylbutyrate
PDH activity in
fibroblasts
Reduced activity
No mutations found
Not performed Normal activity Not performed
Muscle respiratory
Chain complexes (C)
Normal CI, II, II, IV activ-
ities
Not performed Decreased Complex III
activity
Not performed
Other AUH and multiple single
gene tests known to
cause LS all negative
SURF1 genetics was ne-
gative
Multiple single gene tests
and WES negative
Single gene tests and
WES all negative
Results in bold indicate abnormal findings. AC5 acylcarnitines; C4OH/isoC4OH5 hydroxybutyryl/hydroxyisobutyryl-carnitine; DBS5dried blood spot;
LS5 Leigh syndrome; 3-MGC53-methylglutaconate; 3-HIVA53-hydroxyisovalerate; MMA5methylmalonic acid; PDH5pyruvate dehydrogenage
activity.
FITZSIMONS ET AL. | 5
3 | METHODS
3.1 | Ethical compliance
Informed consent was obtained from both sets of parents for routine
and investigative studies.
Consent was obtained from the parents of family two for whole
exome sequencing (WES) of two affected siblings (Patient 3 and
Patient 4) according to Temple Street Children’s University Hospital
procedures. Consent was given to use Patient 2 archived new born
blood spot screening card for molecular genetic studies.
3.2 | Metabolite analysis
Urine erythro-2,3-dihydroxy-2-methylbutyrate was detected as a
trimethylsilyl derivative on routine organic acid analysis by
standard gas chromatography-mass spectrometry. Separation from
threo-2,3-dihydroxy-2-methylbutyrate was noted and erythro-2,3-dihy-
droxy-2-methylbutyrate was quantified in urine as described by Peters
et al. (2014) in Patient 1 and Patient 4 only.
Spectra for both isomers are similar with notable ion at m/z 306
(Figure 3b); however, they are separated on standard GC/MS organic
acid chromatography, with erythro-2,3-dihydroxy-2-methylbutyrate
eluting approximately 0.2 minute earlier than threo-2,3-dihydroxy-2-
methylbutyrate.
Acylcarnitine analysis of butyl derivatives on dried blood spots
(DBSs) was performed by standard tandem mass spectrometry meth-
ods on Patients 1, 3, and 4.
Semi-quantitative urine screening for methacrylate and acrylate
derivatives was performed on urine from Patient 1 and Patient 4 only.
Analysis was by flow injection tandem mass spectrometry of butyl
FIGURE 2 (a) MRI image of Patient 2 at 9 months of age. Axial T2W image at the basal ganglia level demonstrating symmetrical
hyperintense foci involving the lentiform nuclei and caudate heads. The thalami are spared. (b) MRS of Patient 2 at 9 months of age. Long
TE MRS with left basal ganglia sampling demonstrating a lactate peak at 1.3 ppm. (c) MRI image of Patient 3 at 8 months of age. Axial T2W
image at midbrain level, demonstrating bilateral symmetrical hyperintensity of the cerebral crura and subtle hyperintensity of the
periaqueductal gray matter
FIGURE 3 (a) Urine organic acid total ion chromatogram of Patient 1 with ECHS1 deficiency. 3-hydroxyisovalerate (eluting at 16 min),
erythro-2,3-dihydroxy-2-methylbutyrate (eluting at 22.2 min), and 3-methyglutaconate (2 peaks eluting at approximately 23.5 and 24.5 min)
are increased. Internal standards are heptanoylglycine and heptadecanoate (eluting at 32 min and 42 min, respectively). (b) GC/MS Spectra
of erythro-2,3-dihydroxy-2-methylbutyrate which elutes separately and just before its threo isomer
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derivatives as previously described by Peters et al. (2015). Quantitation
of urine cysteine, cysteamine, glycine, methacrylyl-CoA and acryloyl-
CoA conjugates and the separation of 3-hydroxybutyrylcarnitine
(C4OH-carnitine), 3-hydroxyisobutyryl carnitine (isoC4OH-carnitine),
and erythro-2,3-dihihydroxy-2-methylbutyrate is described by Peters
et al. (2015).
3.3 | SCEH enzyme activity measurement
Measurement of SCEH enzyme activity and immunoblotting, were per-
formed in cultured skin fibroblasts from Patient 1 and Patient 3 as
described in Peters et al. (2014).
3.4 | Genetic analyses
All exons and flanking intronic sequences of the ECHS1 gene of Patient
1 were Sanger sequenced after amplification by PCR from genomic
DNA isolated from cultured fibroblasts and using a BigDye Terminator
cycle sequencing kit (Applied Biosystems, Foster City, CA).
WES was conducted on Patients 3 and 4 according to standard
protocols as previously reported (Besse et al., 2015; Bonnen et al.,
2013). Additional di-deoxy Sanger sequencing analysis of ECHS1 exon
5 was undertaken using DNA from Patients 2 to 4 (three clinically
affected siblings) and their unaffected parents. Molecular genetic inves-
tigations for Patient 2, the oldest sibling in Family 2, was undertaken
using DNA obtained from his archived newborn bloodspot screening
card.
4 | RESULTS
4.1 | Laboratory investigations and metabolite results
4.1.1 | Patient 1
Initial biochemical investigations showed elevated lactate in both
plasma and CSF. There was no significant increase in plasma lactate
post feed. Plasma alanine was elevated initially; however, plasma pro-
line was increased on five out of six occasions measured. Other amino
acids were essentially normal in plasma and CSF including branched-
chain amino acids (BCAA). Urine organic acid analysis on all four occa-
sions showed abnormal increase in excretion of 3-methylglutaconate
(3MGC) and erythro-2,3-dihydroxy-2-methylbutyrate, with mild keto-
nuria noted on one sample. Excretion of 3-hydroxisovalerate was
increased slightly on all four occasions but this was not reflected in the
acylcarnitine analysis (Figure 3a). The DBS acylcarnitine profile showed
a slight increase in signal at m/z 304 hydroxybutyrylcarnitine/hydroxyi-
sobutyrylcarnitine (C4OH/isoC4OH-carnitine). This was attributed to
C4OH-carnitine, reflecting the mild ketosis noted in urine collected at
the same time.
Lactate/pyruvate ratio was measured in perchloric acid de-
proteinised blood and values ranged from 6.9 to 15.2 (reference range
12–20). PDH complex (PDHc) activity in cultured skin fibroblasts (per-
formed as described by Wicking, Scholem, Hunt, and Brown (1986)
was slightly decreased at 0.58 nmol/mg protein/min (reference range
0.7–1.1). Analysis of MT-ATP8 and MT-ATP6 genes associated with LS
and analysis of PDH genes and AUH gene revealed no known or candi-
date pathogenic variants.
4.1.2 | Patient 2
Plasma lactate was marginally increased with essentially normal plasma
alanine and proline. Other amino acids were essentially normal includ-
ing BCAA. Urine organic acids performed on one occasion showed an
abnormal increase in excretion of (3MGC) and erythro-2,3-dihydroxy-2-
methylbutyrate. DBS acylcarnitines were not analyzed. He had no
mutations in the SURF1 gene. Skin or muscle biopsies were not con-
sented and no further investigations were performed prior to death
(Table 3).
4.1.3 | Patient 3
Plasma lactate increased with progression of disease while plasma ala-
nine and proline levels remained within reference range. Other amino
acids were essentially normal including branched-chain amino acids.
There was a significant increase in plasma lactate from 1.71 to 3.39
mmol/L (reference range 0.6–2.4 mmol/L) 60 min post ingestion of a
glucose load. Urine organic acids performed on two occasions showed
an abnormal increase in excretion of 3-MGC and erythro-2,3-dihy-
droxy-2-methylbutyrate, and a marked lactate excretion reflecting
increased plasma lactate at time of collection. There was a slight
increase in methylmalonic acid (MMA) excretion on the initial urine
organic acid analysis which normalized on subsequent testing. DBS
acylcarnitine analysis revealed a slightly low free carnitine with slightly
decreased long chain acylcarnitines, probably reflecting poor feeding,
and low carnitine intake. There was no increase in C4OH/isoC4OH-car-
nitine nor methylmalonyl/succinyl-carnitine (C4DC) making either
succinyl-CoA ligase ADP forming b-subunit (SUCLA2) or succinate-
CoA-ligase a-subunit (SUCLG1) deficiency unlikely. Both of these con-
ditions are associated with elevated plasma lactate, increased MMA
and basal ganglia involvement on neuroimaging (Carrozzo et al., 2007;
Ostergaard et al., 2010).
PDH activity and fatty acid b-oxidation studies in skin fibroblasts
was normal. The activities of respiratory chain complexes I, II, and IV
were normal within a frozen muscle homogenate although the activity
of complexes II1 III (representing complex III) was found to be
decreased in her skeletal muscle. The patient did not have the common
mitochondrial DNA mutations. Similarly, she did not have the common
pathogenic POLG variants associated with Alpers’ syndrome. A novel
m.12173T>C variant of uncertain pathogenicity within the MTTH
gene (encoding mt-tRNAHis) was identified but further analyses were
not pursued as it did not segregate within the family with a clinically
affected status. Analysis of large-scale mtDNA rearrangements demon-
strated no detectable mtDNA deletions or duplications and WES
yielded no candidate variants (Table 3).
4.1.4 | Patient 4
Plasma lactate levels increased with disease progression while plasma
alanine and proline levels remained within reference range similar to
those of his sister though they were only measured in the neonatal
period. Other amino acids were also normal including branched-chain
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amino acids. Initial urine organic acids performed showed an abnormal
increase in excretion of 3-MGC similar to his siblings and was persis-
tent in all six urines. There was a slight increase in excretion of MMA in
the second and third samples which normalized with later testing. A
mild dicarboxylic aciduria was present in one profile reflecting lipolysis,
probably secondary to resolving ketosis. Excretion of erythro-2,3-dihy-
droxy-2-methylbutyrate while detectable in all six urines was not con-
sidered significant enough for comment on qualitative analysis during
earlier sampling and was only considered to be increased when he was
approximately 5 months of age. The acylcarnitine profile was normal
and neither C4OH/isoC4OH-carnitine nor methylmalonyl/succinyl-car-
nitine (C4DC) were increased. As with his two siblings, analysis of
mtDNA genes commonly associated with LS and WES did not identify
a genetic cause. Skin and muscle biopsies were not consented (Table 3).
All four patients had overlapping biochemical abnormalities; elevated
plasma lactate, with or without increased plasma alanine and proline,
3-methylglutaconic aciduria with elevated erythro-2,3-dihydroxy-2-
methylbutyrate and usually normal C4OH/isoC4OH-carnitine and nor-
mal branched-chain amino acid levels.
Quantitative analysis of erythro-2,3-dihydroxy-2-methylbutyrate
confirmed that levels were significantly increased in the urine of
Patient 1 and Patient 4 (Table 3). Excretion of 3-MGC was increased in
all samples from all four patients. Notable was also the mild excretion
of methylmalonic acid, a propionate metabolite downstream from
SCEH and HIBCH on the valine degradation pathway, in Patients 3 and
4 and mildly increased excretion of 3-hydroxyisovalerate, a leucine
metabolite, in all four samples from Patient 1. None of these metabo-
lites were reflected in acylcarnitine analysis. Propionylcarnitine (C3),
methylmalonyl/succinyl-carnitine (C4DC), and hydroxyisovaleryl-
carnitine (C5OH) were all within the reference range in three of the
patients where acylcarnitine profiling was performed. Patient 1 had
mild ketonuria in one of his four urines and Patient 4 had one urine
which was mildly lipolytic; however, neither he nor the other three
patients showed any markers of impaired mitochondrial b-oxidation in
either urine organic acid profile or acylcarnitine profile on DBS analysis
where samples were available.
LC-MS/MS analysis (Peters et al., 2015) of urine from Patients 1
and 4 revealed increased excretion of methacrylyl-CoA and acryloyl-
CoA related metabolites without significant increases of isoC4OH-car-
nitine; this metabolic profile was highly suggestive of SCEH deficiency
(Table 4).
4.2 | SCEH enzyme activity measurement and
immunoblotting
SCEH enzyme activity was measured in the fibroblasts of Patients 1
and 3 only. SCEH enzyme activity was markedly reduced in fibroblasts
of Patient 1 (40 nmol/(min.mg protein)) and Patient 3 (27 nmol/[min.
mg protein]) compared to the reference values (199–670 nmol/[min.
mg protein]). Immunodetection of steady-state SCEH protein in fibro-
blast homogenates of Patient 1 and 3 by western blotting revealed the
absence of the 27 kDa band corresponding to SCEH (Ferdinandusse
et al., 2015).
4.3 | ECHS1 genetic analyses
4.3.1 | Family 1
Patient 1 was apparent homozygous for a previously reported
c.476A>G, p.(Gln159Arg) variant (Haack et al., 2015) in exon 4 of the
ECHS1 gene (GenBank Accession Number: NM_004092.3) corroborat-
ing the enzymatic diagnosis of SCEH deficiency. The c.476A>G,
p.(Gln159Arg) ECHS1 variant has been previously reported in either the
homozygous or compound heterozygous state in clinically affected
patients (Haack et al., 2015). Unfortunately, parental DNA samples
were not available to confirm the apparent homozygosity in Patient 1.
4.3.2 | Family 2
Initial WES analysis of Patients 3 and 4 did not identify any potentially
pathogenic variants, but following a biochemical diagnosis of SCEH
deficiency in Patient 3, reanalysis of the exome data at the ECHS1 locus
revealed exon 5 was not captured in this exome assay, and had no cor-
responding sequencing data, despite an average 1003 coverage
exome-wide. Sanger sequencing of exon 5 identified a previously
TABLE 4 Urine metabolite results (mmol/mmol creatinine) LC-MS/MS in patients with ECHS1 deficiency
Controls
LC-MS/MS Range n Patient 1 Patient 4
ECHS1
positive
HIBCH
positive
Acryloyl cysteamine <1.2 19 2.0 2.6 6.5 12.2
Acryloyl-L-cysteine <2.2 19 1.9 2.3 5.7 3.8
N-acetyl-acryloyl-cysteine <9.0 9 15.6 13.1 43.4 10.0
Methacryl-cysteamine <10 19 8.6 9.4 23.4 13.0
Methacryl-L-cysteine <5.3 19 11.9 9.7 32.0 26.6
N-acetyl methacryl-cysteine <0.4 9 3.9 3.0 10.8 6.6
S-(2-carboxypropyl)cysteine carnitine ester (UMS/MS) <0.4 334 1.1 1.1 25.2 5.3
3-hydroxyisobutyryl carnitine(isoC4OH) <0.38 9 0.48 0.2 0.1 6.79
Erythro-2,3-dihydroxy-2-methylbutyrate (GC/MS) <25 48 492 322 2,370 704
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reported homozygous c.538A>G, p.(Thr180Ala) ECHS1 variant in
Patients 2, 3, and 4 (Tetreault et al., 2015). Analysis of parental samples
confirmed recessive inheritance of the c.538A>G, p.(Thr180Ala)
ECHS1 variant in this family (Figure 4).
5 | DISCUSSION
This case series was part of a retrospective study performed following
the publication that the presence of erythro-2,3-dihydroxy-2-methylbu-
tyrate in urine had been identified in some patients with SCEH and
HIBCH deficiency. This review involves four patients from two families
where no definitive cause of death was made at the time of death in
two of the index cases in each family.
All four patients were diagnosed with SCEH deficiency and had
similar clinical features and progression. They all had significant devel-
opmental delay. Central hypotonia was a common early sign. Faltering
growth and progressive feeding problems were prominent in all cases.
As the clinical syndrome progressed, seizures and apneic episodes
became more frequent and severe. Neuroimaging of all four patients
showed progressive bilateral symmetrical lesions in basal ganglia in
keeping with LS (Baertling et al., 2014; Leigh, 1951). Cerebral and
cerebellar atrophy and a lactate doublet peak on MRS of the left basal
ganglia was present in three out of the four patients. All four patients
had overlapping biochemical abnormalities; elevated plasma lactate,
with or without increased plasma alanine and proline, 3-
methylglutaconic aciduria (3-MGA) with elevated erythro-2,3-dihy-
droxy-2-methylbutyrate and normal hydroxyisoC4OH-carnitine and
branched-chain amino acid levels.
Increased urine excretion of methacrylyl-CoA and acryloyl-CoA
related metabolites analyzed by LC-MS/MS pointed to SCEH defi-
ciency. SCEH enzyme activity was markedly reduced in fibroblasts and
both families harbor homozygous ECHS1 mutations.
All four patients had increased excretion of erythro-2,3-dihydroxy-
2-methylbutyrate; this metabolite derived from acryloyl-CoA was origi-
nally described in SCEH deficiency in 2014 by Peters et al. Latter
patient reports document concentrations of varying magnitude (Bed-
oyan et al., 2017; Ferdinandusse et al., 2015; Peters et al., 2015) and
that levels may be unreliable shortly after birth (Ganetzky et al., 2016)
which was the case in Patient 4. Two out of four patients had
increased methylmalonic acid which has been reported previously in a
patient with SCEH deficiency (Tetreault et al., 2015).
All four of patients had consistent elevated levels of 3-MGC
detected in their urine samples and Patient 1 had elevated 3-HIVA
FIGURE 4 (a) Sequencing chromatograms showing the homozygous c.476A>G, p.(Gln159Arg) ECHS1 variant in Family 1 and the
c.538A>G, p.(Thr180Ala) ECHS1 variant in Family 2. (b) Conservation studies support the evolutionary importance of the p.Gln159 and p.
Thr180 residues [Color figure can be viewed at wileyonlinelibrary.com]
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although his AUH gene sequencing was negative. In primary 3-MGA,
deficiency of 3-methyl glutaconyl Co A hydratase due to mutations in
the AUH gene are directly responsible for the accumulation of 3MGC
while in secondary 3MGA, no defect in leucine catabolism exists and
the metabolic origin of 3MGC is unknown (Su & Ryan, 2014). Increased
3-HIVA has been previously reported in a 1-year-old male patient
(Ferdinandusse et al., 2015) and increased excretion of 3-MGC has
been reported previously in at least one case of SCEH deficiency, a 7-
year-old female and may represent a later biochemical feature in milder
cases (Ferdinandusse et al., 2015) and noted to be increased transiently
following long-term follow-up (Huffnagel et al., 2017). All of our
patients were from consanguineous unions so it is possible that excre-
tion of 3-MGC is not related to ECHS1 mutations but to a separate
condition or secondary to mitochondrial dysfunction.
There is a rapidly growing group of IEMs with a syndromic pheno-
type reviewed by Wortmann, Kluijtmans, Engelke, Wevers, and Morava
(2012) and Wortmann et al. (2013) causing secondary 3-
methylglutaconic aciduria (3-MGA) due to defective phospholipid
remodeling or mitochondrial membrane associated disorders. The
excretion of 3-MGC can be highly variable or intermittently normal in
secondary 3-MGA and is generally less than levels seen in primary 3-
MGA due to AUH. Clinical features of secondary 3-MGA are heteroge-
neous but distinctive, rare, but highly characteristic, neurometabolic
syndromes (Saunders et al., 2015; Wortmann et al., 2013, 2015).
3-MGC is also is a marker not only for mitochondrial dysfunction
in general, but for specific mitochondrial disorders (Mandel et al., 2016;
Olahova et al., 2017; Wortmann et al., 2013).
Our patients had extensive mitochondrial molecular genetic stud-
ies performed. WES data showed no evidence for an alternative etiol-
ogy in the second family so it is less likely that 3-MGC excretion is due
to any of the reported conditions causing secondary 3-MGA and more
likely secondary to non-specified mitochondrial dysfunction. Further-
more, we are aware of 4 out of 4 ECHS1 deficient patients from Mel-
bourne with persistently increased 3MGC excretion (unpublished
observations and personal communications), indicating that ECHS1
deficiency should be added to the growing list of causes of 3MGA.
Secondary PDHc and respiratory chain complex deficiencies have
been reported with SCEH deficiency, as previously stated. Only Patient
1 and Patient 3 had muscle biopsies performed, showing a mild second-
ary PDH deficiency in Patient 1 while Patient 3 had reduced complex
III activity, which would support published data (Bedoyan et al., 2017;
Ferdinandusse et al., 2013; Sakai et al., 2015).
A wide phenotypic spectrum is now emerging for SCEH deficiency,
ranging from lethality in the first days of life to adult patients who may
not fulfill all criteria for LS. Urine metabolite levels correlate with clini-
cal severity and specific separation of isoC4OH and OH-C4-carnitine
isomers can distinguish between SCEH and HIBCH deficiency (Al
Mutairi et al., 2017; Bedoyan et al., 2017; Ganetzky et al., 2016; Haack
et al., 2015; Nair et al., 2016).
The increased excretion of methacrylyl-CoA, acryloyl-CoA adducts,
and erythro-2,3-dihydroxy-2-methylbutyrate in the two patients quanti-
tated by LC-MS/MS are consistent with SCEH deficiency; however,
they are less than those previously reported in clinically severe cases
(James Pitt, unpublished observations; Peters et al., 2014, 2015). Evi-
dence is emerging that metabolite levels may correlate with disease
severity, being subtle or normal for some metabolites in clinically milder
cases (Haack et al., 2015; Yamada et al., 2015) and retrospective analy-
sis of S-(2-carboxypropyl)cysteamine, S-(2-carboxypropyl)cysteine, and
N-acetyl-S-(2-carboxypropyl) cysteine can be a diagnostic clue in the
disease spectrum of ECHS1 deficiency (A Mutairi et al., 2017). SCEH
activity in cultured fibroblasts was markedly reduced but not com-
pletely deficient, which is in agreement with a milder clinical phenotype
considering the age of death when compared to some other published
cases (Bedoyan et al., 2017; Haack et al., 2015; Peters et al., 2014).
Ferdinandusse et al. investigated the role of SCEH in fatty acid and
branched-chain amino acid metabolism in four patients with mutations
in ECHS1 and results from their enzyme activity measurements and
immunoblot analysis strongly suggest that there is a correlation
between the residual SCEH enzyme activity and the severity of the
clinical symptoms (Ferdinandusse et al., 2015). In addition, excretion of
2,3-dihydroxy-2-methylbutyrate may not have been reported or
checked in some historical cases because its significance was not
known at the time; it may be a more common biochemical feature of
SCEH deficiency than we are aware of.
The underlying genetic cause of the SCEH deficiency observed in
Patient 1 is a previously reported homozygous c.476A>G
(p.Gln159Arg) pathogenic ECHS1 variant associated with functional
SCEH enzyme deficiency, thereby confirming the clinical diagnosis. Of
interest, Family 3 in a previously reported cohort of patients with
ECHS1-related disease (Haack et al., 2015) is also of Pakistani origin,
raising the possibility that the p.(Gln159Arg) variant may represent a
founder mutation in this population.
The c.538A>G, p.(Thr180Ala) ECHS1 homozygous variant identi-
fied in Family 2 (Patients 2, 3, and 4) has been previously reported with
the suggestion that it may represent a single French-Canadian ancestral
mutation (Tetreault et al., 2015). Follow-up data presented here sup-
ports a shared haplotype involving the reported French-Canadian cases
and our Irish Traveler family, thus we propose this variant has an Irish
ancestral origin with subsequent migration to Canada.
Canadian immigration history dates back to the 17th century when
the land was colonized first by the French in Quebec and then by the
British in Newfoundland. Many thousand men from the South East of
Ireland where Family 2 originates played their part in early Newfound-
land history. The Irish arrived in more significant numbers in the 1760s
and another sizeable group of Irish immigrants arrived in 1823–1825.
In 1847 alone at the time of The Great Irish Famine close to 100,000
arrived in Grosse Isle, an island in present day Quebec. Family 2 are
members of the Irish Travelling Community. Gilbert, Carmi, Ennis,
Wilson, and Cavalleri (2017) demonstrated evidence for population
substructure within the Irish Traveler population, and estimate a time
of divergence from the settled Irish before the Great Famine of 1845–
1852.
Genotypes analysis of SNPs surrounding the c.538A>G,
p.(Thr180Ala) ECHS1 mutation were extracted from the WES data for
Patients 3 and 4 and compared to data from the original Tetreault et al.
(2015) study (Supporting Information Table S1) which showed a
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common haplotype spanning at least 1,200 Mb around the ECHS1
locus, supporting a common founder.
WES has accelerated the discovery of new genes and pathways
involved in LS, providing novel insights into the pathophysiological
mechanisms. No general curative treatment is available for this devas-
tating disorder, although several recent studies imply that early treat-
ment might be beneficial for some patients depending on the gene or
process affected, for example, the ketogenic diet has been noted to be
helpful in patients with PDHc deficiency and some patients with PDHc
deficiency and LS may show small benefits from vitamin or co-factor
supplementation with coenzyme Q10, thiamine or riboflavin (Baertling
et al., 2014; Gerards, Sallevelt, & Smeets, 2016; Sofou et al., 2014).
Mahajan, Constantinou, and Sidiropoulos (2017) describe a case of
ECHS1 deficiency-associated paroxysmal exercise-induced dyskinesias
with initial symptomatic improvement after 3 months treatment with a
mitochondrial cocktail. Soler-Alfonso et al. (2015) proposed that valine
restriction made significant improvement in bilateral ptosis and postural
tone of their one HIBCH deficient patient when plasma valine was low-
ered to 83 mmol/L (reference range 82–293). However, valine restric-
tion alone may not be effective because it was shown that it did not
decrease valine levels in rat brain (Hutchison, Zarghami, Cusick,
Longenecker, & Haskell, 1983). Restricting leucine, isoleucine, and
valine (i.e. a Maple Syrup Urine Disease diet) does decrease brain valine
levels so this approach may show better benefits. CSF valine is normal
in SCEH/HIBCH deficiency, and the methacrylyl-CoA and acryloyl-CoA
toxic metabolites are three steps downstream in the valine pathway.
Therefore, decreasing cerebral valine may not make a significant impact
on the accumulation of toxic metabolites. Treatment with cysteamine
and/or N-acetylcysteine is both safe and widely used and cross the
blood brain barrier. Some benefits have been shown in Huntington’s
disease, Parkinson’s disease and Alzheimer’s disease, some aspects of
which involve glutathione depletion, by enhancing natural detoxifica-
tion (Besouw, Masereeuw, van den Heuvel, & Levtchenko, 2013). Cur-
rently, there is no direct evidence of cerebral glutathione depletion in
ECHS1 or HIBCH gene defects. However, a fully functional glutathione
system may still not be efficient enough to prevent damage from accu-
mulating methacrylyl-CoA and treatment with cysteamine or N-acetyl-
cysteine may be a useful adjunct to the detoxification of these
metabolites.
6 | CONCLUSION
The presence of detectable erythro-2,3-dihydroxy-2-methylbutyrate in
urine is a nonspecific biochemical finding. 3MGA is not a discriminative
feature but a minor finding in the biochemical phenotype of ECHS1
deficiency; however, in combination with increased excretion of
erythro-2,3-dihydroxy-2-methylbutyrate, elevated plasma lactate and
normal acylcarnitine profile in a patient with LS should prompt consid-
eration of SCEH deficiency.
It is a known limitation of WES that not all nucleotides of every
coding exon are captured. This can be due to the nature of the primary
sequence, for example GC-rich and repetitive regions are not well
ascertained by hybridization-based capture assays. Additionally, multi-
ple different gene annotation systems exist that do not show complete
agreement and capture assays have been designed according to best
approximations of genic structures. In this study, WES was conducted
to an exome-wide average coverage of 100x, however, there were no
reads present in ECHS1 exon 5. This underlines the importance of tak-
ing into account coverage when interpreting exome results.
Our report also highlights that biochemical analyses remain the
gold standard for the diagnosis of some patients with inborn errors of
metabolism and, where possible, a molecular genetic diagnosis should
always be contextualized with functional (e.g. biochemical) data.
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